Lista de obras - Heidi Greulich - Dominio Público Uruguay

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

artículo científico publicado en 2013

Activating mutations in ALK provide a therapeutic target in neuroblastoma

artículo científico publicado en 2008

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

artículo científico publicado en 2010

Characterizing genomic alterations in cancer by complementary functional associations

artículo científico publicado en 2016

Characterizing the cancer genome in lung adenocarcinoma

artículo científico publicado en 2007

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

artículo científico publicado en 2010

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

artículo científico publicado en 2014

Drug-sensitive FGFR2 mutations in endometrial carcinoma

artículo científico publicado en 2008

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

artículo científico publicado en 2004

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

artículo científico publicado en 2006

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

artículo científico publicado en 2005

Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer

article

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

artículo científico publicado en 2012

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

artículo científico publicado en 2009

High-throughput oncogene mutation profiling in human cancer

article

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance

artículo científico publicado en 2008

Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.

artículo científico publicado en 2015

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel

artículo científico publicado en 2008

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer

artículo científico publicado en 2011

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

scholarly article

Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome

artículo científico publicado en 2011

Integrative genomic approaches identify IKBKE as a breast cancer oncogene

artículo científico publicado en 2007

Landscape of genomic alterations in cervical carcinomas

artículo científico publicado en 2013

MEDULLOBLASTOMA

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

artículo científico publicado en 2012

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

artículo científico publicado en 2012

Modeling genomic diversity and tumor dependency in malignant melanoma

artículo científico publicado en 2008

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

artículo científico publicado en 2011

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

artículo científico publicado en 2006

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

artículo científico publicado en 2014

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

artículo científico publicado en 2005

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions

scientific article published on 18 May 2009

Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features

artículo científico publicado en 2011

SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines

artículo científico publicado en 2008

SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients

artículo científico publicado en 2008

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

artículo científico publicado en 2006

Somatic mutations affect key pathways in lung adenocarcinoma

artículo científico publicado en 2008

Somatic mutations are present in all members of the AKT family in endometrial carcinoma

artículo científico publicado en 2009

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

artículo científico publicado en 2007

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

artículo científico publicado en 2010

Targeting mutant fibroblast growth factor receptors in cancer

artículo científico publicado en 2011

The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies ⬇️

artículo científico publicado el 1 de diciembre de 2010

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

artículo científico publicado en 2008

The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor

artículo científico publicado en 2008

The landscape of somatic copy-number alteration across human cancers

artículo científico publicado en 2010

Lista de obras de Heidi Greulich

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

Activating mutations in ALK provide a therapeutic target in neuroblastoma

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

Characterizing genomic alterations in cancer by complementary functional associations

Characterizing the cancer genome in lung adenocarcinoma

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab

Drug-sensitive FGFR2 mutations in endometrial carcinoma

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy

High-throughput oncogene mutation profiling in human cancer

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance

Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome

Integrative genomic approaches identify IKBKE as a breast cancer oncogene

Landscape of genomic alterations in cervical carcinomas

MEDULLOBLASTOMA

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

Modeling genomic diversity and tumor dependency in malignant melanoma

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions

Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features

SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines

SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

Somatic mutations affect key pathways in lung adenocarcinoma

Somatic mutations are present in all members of the AKT family in endometrial carcinoma

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

Targeting mutant fibroblast growth factor receptors in cancer

The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies ⬇️

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor

The landscape of somatic copy-number alteration across human cancers